Glutamate and multiple sclerosis

Current Medicinal Chemistry

Volumn 19, Issue 9, 2012, Pages 1295-1299

  Frigo, M ^a   Cogo, M G ^b   Fusco, M L ^b   Gardinetti, M ^b   Frigeni, B ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

demyelination; Glutamate; inflammation; multiple sclerosis; neurodegeneration

Indexed keywords

ANTIOXIDANT; CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT;

ALLERGIC ENCEPHALOMYELITIS; CELL INFILTRATION; CELL LOSS; DEMYELINATION; HUMAN; INFLAMMATION; LEUKOCYTE; MICROGLIA; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; GLUTAMIC ACID; HUMANS; MULTIPLE SCLEROSIS; OXIDATIVE STRESS;

EID: 84858113020     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799462559     Document Type: Review

References (50)

1. Flanagan, E.M.; Erickson, J.B.; Viveros, O.H.; Chang, S.Y.; Reinhard, J.F. Jr. Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis. Journal of Neurochemistry, 1995, 64(3):1192-1196.
2. Sarchielli, P.; Greco, L.; Floridi, A.; Floridi, A.; Gallai, V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Archives of Neurology, 2003, 60(8):1082-1088. (Pubitemid 36975795)
3. Matute, C. Glutamate and ATP signalling in white matter pathology. J Anat, 2011 Jul, 219(1):53-64.
4. Bolton, C.; Lees, P.; Paul, C.; Scott, G.S.; Williams, K.I.; Woodyer, P. Aspects of the biochemical pharmacology of neurovascular disruption in experimental allergic encephalomyelitis (EAE). Journal of Neuroimmunology, 1994, 52(2):113.
5. Starck, M.; Albrecht, H.; Pollmann, W.; Straube, A.; Dieterich, M. Drug therapy for acquired pendular nystagmus in multiple sclerosis. Journal of Neurology, 1997, 244(1):9-16. (Pubitemid 26413892)
6. Matute, C.; Alberdi, E.; Domercq, M.; Perez-Cerda, F.; Perez-Samartin, A.; Sanchez-Gomez, M.V. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci, 2001, 24:224-230. (Pubitemid 32204379)
7. Mòricz, K.; Gigler, G.; Albert, M. Effects of EGIS-8332,an AMPA antagonist, in transient focal ischemia and multiple sclerosis in rats. Journal of Neuroimmunology, 2004, 154(1-2):86.
8. Szabò, H.; Berzsenyi, P.; Nemét, L.; Andràsi, F.; Horvàth, K. Investigations with AMPA antagonist 2,3-benzodiazepines in the experimental autoimmune encephalomyelitis model in rats. Journal of Neuroimmunology, 2004, 154(1-2):86.
9. Polito, A.; Reynolds, R. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J Anat, 2005, 207, 707-716. (Pubitemid 43019730)
10. Voss, E.; Raab, P.; Trebst, C.; Stangel, M. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Adv Neurol Disord, 2011, 4(2): 123-134.
11. Bertuzzi F.; Suzani M.; Tagliabue E.; Cavaletti G.; Angeli R.; Balgera R.; Rulli E.; Ferrarese C.; Miglior S. Diagnostic validity of optic disc and retinal nerve fiber layer evaluations in detecting structural changes after optic neuritis. Ophthalmology, 2010 Jun;117(6): 1256-1264.
12. Hamilton, N.; Hubbard, P.; Butt, A. Effects of Glutamate receptors activation on NG2-glia in the rat optic nerve. J Anat, 2009, 214, 208-218.
13. Kukley, M.; Capetillo-Zarate, E.; Dietrich, D. Vescicular glutamate release from axons in white matter. Nat Neurosci, 2007, 10, 311-320.
14. Hamilton, N.; Vayro, S.; Kirchhoff, F.; Verkhatsky, A.; Robbins, J.; Gorecki, D.C.; Butt, A.M. Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. Glia, 2008, 56, 734-749
15. Baranzini, S.E.; Srinivasan, R.; Khankhanian, P.; Okuda, D.T.; Nelson, S.J.; Matthews, P.M.; Hauser, S.L.; Oksenberg, J.R.; Pelletier D. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain, 2010 Sep, 133(9):2603-11.
16. Hardin-Pouzet, H.; Krakowski, M.; Bourbonniére, L.; Dider-Bazes, M.; Tran, E.; Owens, T. Glutamate metabolism is downregulated in astrocytes during experimental allergic encephalomyelitis. Glia, 1997, 20(1):79-85. (Pubitemid 27207010)
17. Rothstein, J.D. Neurobiology. Bundling up excitement. Nature, 2000, 407(6801):141-142.
18. Ohgoh, M.; Hanada, T.; Smith, T.; Hashimoto, T.; Ueno, M.; Yamanishi, Y.; Watanabe, M.; Nishizawa, Y. et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2002, 125(1-2):170-178. (Pubitemid 34327467)
19. Kanai, Y.; Trotti, D.; Nussberger, S.; Hediger, M.A. High affinity glutamate transporter family: structure, function and physiological relevance. In: Reith MEA, Totowa, ed. Neurotransmitter Transporters: Structure, Function, and Regulation. NJ:Humana Press; 1997, pp. 171-214.
20. Volterra, A.; Trotti, D.; Tromba, C.; Floridi, S.; Racagni, G. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. The Journal of Neuroscience, 1994, 14(5): 2924-2932. (Pubitemid 24140915)
21. Pitt, D.; Nagelmeier, I.E.; Wilson, H.C.; Raine, C.S. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology, 2003, 61: 1113-20. (Pubitemid 37461947)
22. Su, Z.Z.; Leszczyniecka, M.; Kang, D.C.; Sarkar, D.; Chao, W.; Volsky, D.J.; Fisher, P.B. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory aminoacid transporter2 (EAAT2). Proc Natl Acad Sci USA, 2003, 100 (4), 1955-1960. (Pubitemid 36254555)
23. Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Hoberg, M.D.; Vidensky, S.; Chung, D.S.; Toan S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433, 73-77. (Pubitemid 40101145)
24. Ramos, K.M.; Lewis, M.T.; Morgan, K.N.; Crysdale, N.Y.; Kroll, J.L.; Taylor, F.R.; Harrison, J.A.; Sloane, E.M.; Maier, S.F.; Watkins, L.R. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience, 2010 Sep 15, 169(4):1888-900.
25. Pampliega, .O; Domercq, M.; Soria, F.N.; Villoslada, P.; Rodríguez-Antigüedad, A.; Matute, C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation, 2011, 8:63.
26. Stover, J.F.; Pleines, U.E.; Morganti-Kossmann, M.C.; Kossmann, T.; Lowitzsch, K., Kempski, O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. European Journal of Clinical Investigation, 1997, 27(12):1038-1043. (Pubitemid 28012626)
27. Gurwitz, D. and Kloog, Y. Peroxynitrite generation might explain elevated glutamate and aspartate levels in multiple sclerosis cerebrospinal fluid. European Journal of Clinical Investigation, 1998, 28(9):760-761. (Pubitemid 28432129)
28. Pampliega, O.; Domercq, M.; Villoslada, P.; Sepulcre, J.; Rodriguez-Antiguedad, A.; Matute, C. Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis. J Neuroimmunol, 2008, 195, 194-198.
29. Srinivasan, R.; Sailasuta, N.; Hurd, R.; Nelson, S.; Pelletier, D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain, 2005, 128 (5), 1016-1025. (Pubitemid 40675457)
30. Piani, D.; Frei, K.; Do, K.Q.; Cuenod, M.; Fontana, A. Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett, 1991, 133 (2): 159-62.
31. Leighton, M.P.; Prost, R.W.; Ulmer, J.L.; Smith, M.M.; Daniels, D.L.; Strottmann, J.M.; Brown, W.D.; Hacein-Bey L. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol, 2001, 22: 1813-24. (Pubitemid 33091945)
32. Nedergaard, M.; Takano, T.; Hansen, A.J. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci, 2002, 3, 748-755. (Pubitemid 135706680)
33. King, I.L.; Dickendesher, T.L.; Segal, B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood, 2009, 113, 3190-3197.
34. Kouwenhoven, M.; Teleshova, N.; Ízenci, V.; Press, R.; Link, H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol, 2001, 112(1-2), 197-205.
35. Fallarino, F.; Volpi, C.; Fazio, F.; Notartomaso, S.; Vacca, C.; Busceti, C.; Bicciato, S.; Battaglia, G.; Bruno, V.; Puccetti, C.; Fioretti, M.C.; Nicoletti, F.; Grohmann, U.; Di Marco, R. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med, 2010, 16:897-902.
36. Vrenken, H.; Barkhof, F.; Uitdehaag, B.M.J.; Castelijns, J.A.; Polman, C.H.; Pouwels, P.J.W. NM Spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med, 2005, 53 (2), 256-66. (Pubitemid 40171039)
37. Su, K.G.; Banker, G.; Bourdette, D.; Forte, M. Axonal degeneration in multiple sclerosis: the mithocondrial hypothesis. Curr Neurol and Neurosci Rep, 2009, 9(5), 411-417.
38. Smith, T.; Groom, A.; Zhu, B.; Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nature Medicine, 2000, 6(1):62-66.
39. Rose, J.W.; Hill, K.E.; Watt, H.E.; Carlson, N.G. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. Journal of Neuroimmunology, 2004, 149(1-2):40-49. (Pubitemid 38352856)
40. Trotti, D.; Rossi, D.; Gjesdal, O.; Levy, L.M.; Racagni, G.; Danbolt, N.C.; Volterra, A. Peroxynitrite inhibits glutamate transporter subtypes. The Journal of Biological Chemistry, 1996, 271(11):5976-5979. (Pubitemid 26095396)
41. 2+exchanger. J Neurosci, 1992, 12(2):430-439.
42. Dutta, R.; McDonough, J.; Yin, X.; Peterson, J.; Chang, A.; Torres, T.; Gudz, T.; Macklin, W.B.; Lewis, D.A.; Fox, R.J.; Rudick, R.; Mirnics, K.; Trapp, B.D. Mithocondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol, 2006, 59(3):478-89. (Pubitemid 43358068)
43. Carlson, N.G.; Rojas, M.A.; Redd, J.W.; Tang, P.; Wood, B.; Hill, K.E.; Rose, J.W. Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J of Neuroinflammation, 2010, 7:25.
44. Manabe, Y.; Anrather, J.; Kawano, T.; Niwa, K.; Zhou, P.; Ross, M.E.; Iadecola, C. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol, 2004, 55(5):668-675. (Pubitemid 38544327)
45. Carlson, N.G.: Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res, 2003, 71(1):79-88.
46. Hansson, E. and Rönnbäck, L. On the potential role of glutamate transport in mental fatigue. J. of Neuroinflammation, 2004; I:22.
47. Dutta, R.; Chang, A.; Doud, M.K.; Kidd, G.J.; Ribaudo, M.V.; Young, E.A.; Fox, R.J.; Staugaitis, S.M.; Trapp, B.D. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol, 2011 Mar, 69(3):445-54.
48. Anderson, C.M. and Swanson, R.A. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia, 2000, 32(1):1-14.
49. Roelcke, U.; Kappos, L.; Lechner-Scott, J.; Brunnschweiler, H.; Huber, S.; Ammann, W.; Plohmann, A.; Dellas, S.; Maguire, R.P.; Missimer, J.; Radu, E.W.; Steck, A.; Leenders, K.L. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology, 1997, 48(6):1566-1571.
50. Centonze, D.; Muzio, L.; Rossi, S,; Furlan, R.; Bernardi, G.; Martino, G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ, 2010, 17(10), 1083-1091.